By activating a 3b1 integrin and downstream PI3k/Akt signaling pathway, NG2/MPG was found to promote tumor resistance to antitumour drugs such as doxorubicin, etoposide and carboplatin. Thus, NG2 should represent an effective therapeutic target in several cancer types.
First author on the article - entitled "The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling" - is Martha Chekenya (Department of Biomedicine University of Bergen) and senior authors are Mouldy Sioud and William B. Stallcup (Cancer Research Center, La Jolla, USA).
Chekenya M, Krakstad C, Svendsen A, Netland IA, Staalesen V, Tysnes BB, Selheim F, Wang J, Sakariassen PO, Sandal T, Lønning PE, Flatmark T, Enger PO, Bjerkvig R, Sioud M, Stallcup WB.
The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling.
Oncogene. 2008 May 12.